BIO-RAD LABORATORIES, INC. acquired RainDance Technologies, Inc. for approximately $72.7 million (cash payments at closing of $72.9 million; a separate $10.0 million cash payment for a preexisting condition was recorded in cost of goods sold), a transaction completed in February 2017, structured as all cash.
RainDance Technologies, Inc. operates in Life Science, is based in Billerica, Massachusetts, USA. RainDance Technologies' foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research, enabling ultra-sensitive detection of genetic variations.
RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with potential applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy.
Foundational droplet-microfluidics IP strengthening Bio-Rad's droplet digital PCR position. Extends Bio-Rad's droplet digital PCR leadership into ultra-sensitive genetic detection and liquid-biopsy research. Life Science segment
RainDance's foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets... These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy.Bio-Rad Laboratories FY2018 10-K, Acquisition of RainDance Technologies note
Advisory firms were not disclosed for this transaction.